John McDonald joined Biogen in June 2011 and currently is the VP of Business Development and Mergers & Acquisitions. From May 2006 through June 2011 John was a managing director at MPM Capital, one of the world’s largest science-dedicated venture capital firms, focusing on company formation and supporting portfolio company business development efforts. Working with Millennium Pharmaceuticals, Inc. from April 2000 through May 2006, John was Vice President of Business Development. Prior to April 2000, John worked at both Genentech, Inc. and Genzyme Corporation where he led or participated in various business development transactions.
In his career, John has led or participated in the evaluating, structuring and negotiating of numerous mergers and acquisitions, licenses and strategic alliances, including Biogen’s collaborations with Mitsubishi Tanabe, AGTC, Sangamo BioSciences, UCB, and Portola Pharmaceuticals, Inc. and Biogen’s acquisition of Stromedix, Inc., Millennium's Ex-U.S. collaboration with Ortho Biotech/Johnson & Johnson for VELCADE, the restructuring of Millennium's relationship with Schering-Plough Corp. for INTEGRILIN, and the sale of Millennium's interest in its CAMPATH joint venture, Genzyme’s alliance with BioMarin for ALDURAZYME, and Genentech’s alliances with Xoma Corporation (RAPTIVA), and IDEC Pharmaceuticals (RITUXAN).
John holds a J.D. from the University of California, Hastings College of Law, and an M.B.A., Beta Gamma Sigma, and a B.S., Phi Beta Kappa, from the Haas School of Business, University of California, Berkeley.